Skip to content
  • Add anything here or just remove it...
ImpentriImpentri
  • Home
  • About
  • Imatinib for COVID-19
  • News
  • Exvastat
  • Contact

Design

Another Print Package

Design

FL3 Print Package

Design

Awesome Pencil Poster

Design

Portfolio typography

Design

Flatsome Poster Print

Design

Magazine

Design

  • Home
  • About
  • Imatinib for COVID-19
  • News
  • Exvastat
  • Contact

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101005142.

This Joint Undertaking receives support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.

IMPENTRI IMI2Follow

IMPENTRI IMI2
Imi2Impentri
6 Oct

Congratulations to the team on their paper "Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: lessons from the CounterCovid imatinib study, accepted into #PSPJournal.
See it here https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.12718
@ASCPTjournals

Reply on Twitter 1445711357274255362Retweet on Twitter 14457113572742553621Like on Twitter 14457113572742553621Twitter 1445711357274255362
biljana_parapid
27 Aug

#ESCCongress 2nd talk by Dr Duijvelaar 🇳🇱
Promising results for #Imatinib & announcement for 3 new @WHO solidarity trials ‼️

#Covid19 #vaccination strongly advised by entire panel as risk for post💉 myo-/peri-carditis much lower than 4 acute 🦠

@avolgman @Hragy @NitiCardio

4
Reply on Twitter 1431148653570404354Retweet on Twitter 14311486535704043546Like on Twitter 14311486535704043548Twitter 1431148653570404354
Imi2Impentri
10 May 2021

International COVID-19 trial to restart with focus on immune responses https://www.nature.com/articles/d41586-021-01090-z

Reply on Twitter 1391712907021406210Retweet on Twitter 1391712907021406210Like on Twitter 13917129070214062102Twitter 1391712907021406210
Load More...
Copyright 2022 © Exvastat Ltd
  • Home
  • About
  • Imatinib for COVID-19
  • News
  • Exvastat
  • Contact
    • WooCommerce not Found